Life sciences briefing: Friday, Aug. 24, 2007
(UPDATED at 11am PT on Sunday, 8/26/07: See below.)
Featured companies: Clinical Data, Epidauros Biotechnologie, Precision Therapeutics, UMD, Zars Pharma
UMD to close $8M for menstrual pain and osteoporosis — Cincinnati’s UMD, a developer of vaginal drug-delivery technologies, expects to close up to $8 million in a fifth funding… Continue Reading
Life sciences briefing: Wednesday, Aug. 22, 2007
Featured companies: Alpex Pharma, Applied Computational Technologies, Separation Design Group, ThermalTherapeutics Systems
Switzerland’s Alpex Pharma raises $9M for plop, plop, fizz, fizz drugs– Alpex Pharma, a Mezzovico, Switzerland drug-formulation company, raised $9 million (CHF 10.9 million) in a second round of funding. Investors included BB Biotech Ventures… Continue Reading
Celator: Combining chemo drugs for fun and profit
(UPDATED: See below.)
Is there a better way to combine drugs in cancer chemotherapy? Celator Pharmaceuticals, a Princeton, N.J., venture drug maker that just raised $10 million, aims to find out.
Like Horizon Therapeutics, which we wrote about here, Celator is convinced that combining two existing drugs in… Continue Reading
ProCertus pulls in $2.3M for prevention of chemo, radiation side effects
ProCertus BioPharm, a Madison, Wis., company developing drugs to minimize the side effects of radiation and chemotherapy, raised $2.3 million in a first round of financing. The company will use the money to begin human tests of products such as DermX, which is supposed to… Continue Reading
Roundup: Anemia drugs under assault, stem-cell trial moves forward, medical interventions and poor “quality of death,” and more
Is the bell tolling for EPO? – The news keeps going from bad to worse for the wonder drugs of biotech — the anemia treatments known as ESAs or EPO, shorthand for “erythropoiesis stimulating agents” and “erythropoietin,” respectively. Earlier today, an FDA advisory panel recommended new… Continue Reading